CTLA4 and neoplasm: These results lead us to propose that CRT-NPs reengineer the TME by reducing the population of immunosuppressive myeloid cells such as MDSCs, which, in turn, augments the anti-CTLA4 effect and the resultant T cell action, enhancing the immune cell cytotoxicity and tumor regression.